Affinity Asset Advisors, LLC
Registered adviserFiling Date
Global Rank
#1,511
/ 8,818
▼ 18
Top Industry
Biotechnology
91.8%
Period ended 4 months ago
Filed Aug 13, 2026 · 3mo
23 quarters · since Dec 2020
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Holder type
Registered adviser
Form ADV roster, Oct 1, 2026
Regulatory AUM
$2,451,641,809
Main clients
Pooled investment vehicles
(100% of AUM)
Private funds
2 funds
· Mixed
Focus by fund count, roster of Oct 1, 2026
$2,451,641,809 gross assets
LEI
549300307G5AWN6LYD87
Private funds on Schedule D 7.B.(1)
As filed Mar 28, 2024; SEC's bulk Form ADV archive ends with 2024 filings.
$553,053,373 gross assets in 1 fund
Hedge funds
$553,053,373
(1)
Form ADV history
Monthly rosters from Dec 2019; each row is a run with the same figures, newest first.
| Rosters | Regulatory AUM | Main clients |
|---|---|---|
| Aug 2026 to Oct 2026 | $2,451,641,809 | Pooled investment vehicles (100%) |
| Apr 2026 to Jul 2026 | $1,691,109,331 | Pooled investment vehicles (100%) |
| Apr 2025 to Mar 2026 | $807,900,474 | Pooled investment vehicles (100%) |
| Apr 2024 to Mar 2025 | $553,053,373 | Pooled investment vehicles (100%) |
| May 2023 to Mar 2024 | $237,620,732 | Pooled investment vehicles (100%) |
| Apr 2023 | $237,620,732 | Pooled investment vehicles (100%) |
2 earlier changes not shown.
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Style
Diversified active
Top 10 weight 43.2%, 36.0 effective positions, active share 95.4% against the Russell 2000 as of 2026-06-30; it meets none of the index-like, systematic-like or concentrated tests
Turnover
Medium turnover
62.5% over the last four quarters (30% to under 100%)
Horizon
Medium horizon
Value-weighted holding period 7.3 quarters (4 to under 12)
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 95.4%; sector active share 89.6% against the combined 13F book's sector weights.
Over time 23 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
107 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
6.1%
−0.7 pts
Top 5
26.1%
−0.2 pts
Top 10
41.1%
−1.1 pts
HHI
254
Diversified−13
Portfolio Trend
23 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 97.4% | $2,126,624,666 |
| Unclassified | 1.4% | $31,545,000 |
| Financial Services | 1.2% | $26,091,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
25 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| PRQR | ProQR Therapeutics N.V. | +3,089,658 | 5,543,936 | $10,311,720 | |
| EQ | Equillium, Inc. | +2,873,690 | 4,100,000 | $13,120,000 | |
| SGMT | Sagimet Biosciences Inc. | +1,629,844 | 2,497,864 | $19,308,488 | |
| AVTX | Avalo Therapeutics, Inc. | +1,559,160 | 2,900,000 | $53,592,000 | |
| CATX | Perspective Therapeutics, Inc. | +1,050,000 | 4,214,582 | $14,371,724 | |
| ALEC | Alector, Inc. | +1,010,000 | 1,510,000 | $3,035,100 | |
| SABS | SAB Biotherapeutics, Inc. | +950,000 | 1,525,000 | $5,947,500 | |
| ROIV | Roivant Sciences Ltd. | +950,000 | 3,750,000 | $132,712,500 | |
| IBIO | iBio, Inc. | +900,681 | 4,007,881 | $7,013,791 | |
| LXEO | Lexeo Therapeutics, Inc. | +757,400 | 5,807,611 | $27,034,429 | |
| TSHA | Taysha Gene Therapies, Inc. | +750,000 | 1,750,000 | $11,917,500 | |
| MGNX | Macrogenics Inc | +716,606 | 1,216,606 | $5,620,719 | |
| RLAY | Relay Therapeutics, Inc. | +650,000 | 1,050,000 | $19,645,500 | |
| ANRO | Alto Neuroscience, Inc. | +350,000 | 850,000 | $22,431,500 | |
| CLYM | Climb Bio, Inc. | +272,000 | 972,000 | $12,674,880 | |
| JBIO | Jade Biosciences, Inc. | +200,394 | 840,350 | $18,672,577 | |
| CLDX | Celldex Therapeutics, Inc. | +200,000 | 700,000 | $26,047,000 | |
| INSM | INSMED Inc | +170,000 | 650,000 | $69,303,000 | |
| RVMD | Revolution Medicines, Inc. | +150,000 | 250,000 | $46,820,000 | |
| — | +133,501 | 1,145,391 | $24,339,558 | ||
| STRO | Sutro Biopharma, Inc. | +102,968 | 1,172,487 | $38,926,568 | |
| BLTE | Belite Bio, Inc | +100,000 | 165,000 | $25,407,525 | |
| CGEM | Cullinan Therapeutics, Inc. | +94,500 | 875,760 | $15,947,589 | |
| ORKA | Oruka Therapeutics, Inc. | +90,327 | 590,000 | $56,150,300 | |
| EPRX | Eupraxia Pharmaceuticals Inc. | +60,995 | 1,650,000 | $10,906,500 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
25 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| ZURA | Zura Bio Ltd | −1,100,000 | 1,464,303 | $8,639,387 | |
| TEVA | Teva Pharmaceutical Industries Ltd | −1,026,000 | 374,000 | $12,671,120 | |
| CMPS | COMPASS Pathways plc | −807,300 | 301,183 | $4,261,739 | |
| RZLT | Rezolute, Inc. | −547,641 | 1,000,000 | $5,200,000 | |
| OVID | Ovid Therapeutics Inc. | −491,756 | 10,144,562 | $27,288,871 | |
| OBIO | Orchestra BioMed Holdings, Inc. | −369,150 | 33,400 | $144,121 | |
| COGT | Cogent Biosciences, Inc. | −300,000 | 450,000 | $17,415,000 | |
| — | −297,926 | 987,000 | $131,004,510 | ||
| ALKS | Alkermes plc. | −225,000 | 1,125,000 | $58,950,000 | |
| TRVI | Trevi Therapeutics, Inc. | −200,000 | 1,800,172 | $33,573,207 | |
| NXTC | NextCure, Inc. | −199,866 | 41,960 | $67,136 | |
| KPTI | Karyopharm Therapeutics Inc. | −187,500 | 312,500 | $3,053,125 | |
| CYTK | Cytokinetics Inc | −150,483 | 550,000 | $46,854,500 | |
| SGP | SpyGlass Pharma, Inc. | −118,414 | 131,586 | $2,929,104 | |
| ANAB | Anaptysbio, Inc | −113,891 | 826,109 | $55,762,357 | |
| ERAS | Erasca, Inc. | −100,000 | 5,250,000 | $96,180,000 | |
| ELVN | Enliven Therapeutics, Inc. | −86,904 | 500,000 | $25,375,000 | |
| XENE | Xenon Pharmaceuticals Inc. | −80,000 | 1,595,000 | $96,274,200 | |
| MBX | MBX Biosciences, Inc. | −75,000 | 75,000 | $4,140,000 | |
| ABVX | Abivax S.A. | −75,000 | 330,000 | $43,975,800 | |
| ASND | Ascendis Pharma A/S | −65,000 | 30,000 | $8,001,600 | |
| TYRA | Tyra Biosciences, Inc. | −57,500 | 200,012 | $6,388,383 | |
| AVBP | ArriVent BioPharma, Inc. | −50,000 | 125,000 | $4,342,500 | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | −50,000 | 150,000 | $12,226,500 | |
| CRSP | CRISPR Therapeutics AG | −50,000 | 100,000 | $5,454,000 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
16 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| TRAX | First Tracks Biotherapeutics, Inc. | 2,032,012 | $40,884,081 | |
| IDYA | IDEAYA Biosciences, Inc. | 400,000 | $14,908,000 | |
| ODTX | Odyssey Therapeutics, Inc. | 766,346 | $14,338,333 | |
| QURE | uniQure N.V. | 175,000 | $8,060,500 | |
| ASMB | Assembly Biosciences, Inc. | 190,000 | $5,221,200 | |
| COAG | Hemab Therapeutics Holdings, Inc. | 138,030 | $5,069,841 | |
| RACC | Research Alliance Corp III | 370,000 | $3,959,000 | |
| AMAN | Amanat Acquisition Corp. | 375,000 | $3,810,000 | |
| BHVN | Biohaven Ltd. | 250,000 | $3,720,000 | |
| FTH | Faeth Therapeutics, Inc. | 144,404 | $3,610,100 | |
| JATT | JATT II Acquisition Corp. | 200,000 | $2,272,000 | |
| NMRA | Neumora Therapeutics, Inc. | 1,070,651 | $1,820,106 | |
| AMLX | Amylyx Pharmaceuticals, Inc. | 98,999 | $1,778,022 | |
| SPRB | Spruce Biosciences, Inc. | 30,000 | $1,620,000 | |
| EIKN | Eikon Therapeutics, Inc. | 98,001 | $1,278,913 | |
| BOLD | Boundless Bio, Inc. | 250,000 | $625,000 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
7 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| CNTA | Centessa Pharmaceuticals plc | 1,400,000 | $55,608,000 | |
| — | 362,764 | $41,652,562 | ||
| — | 562,631 | $29,661,906 | ||
| BBIO | BridgeBio Pharma, Inc. | 150,000 | $11,139,000 | |
| WVE | Wave Life Sciences, Inc. | 1,401,727 | $10,162,520 | |
| CORT | Corcept Therapeutics Inc | 50,000 | $2,015,500 | |
| — | 229,076 | $1,699,744 | ||
| No positions match the current search. | ||||
107 tracked positions ·
$2,184,260,666 total
· filing declares
113 positions · $2,212,480,490
· as of Jun 30, 2026
Showing 1–50
of 107 positions by value
· page 1 of 3
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| ROIV |
Roivant Sciences Ltd.
Healthcare
|
Added | 3,750,000 | $132,712,500 | 6.08% | |
|
|
Reduced | 987,000 | $131,004,510 | 6.00% | ||
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
Held | 1,279,134 | $113,561,516 | 5.20% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
Reduced | 1,595,000 | $96,274,200 | 4.41% | |
| ERAS |
Erasca, Inc.
Healthcare
|
Reduced | 5,250,000 | $96,180,000 | 4.40% | |
| ALKS |
Alkermes plc.
CALL
+ SHARES
Healthcare
|
Added | 1,375,000 | $72,050,000 | 3.30% | |
| INSM |
INSMED Inc
Healthcare
|
Added | 650,000 | $69,303,000 | 3.17% | |
| MRNA |
Moderna, Inc.
PUT
CALL
Healthcare
|
Added | 975,000 | $68,279,250 | 3.13% | |
| PRAX |
Praxis Precision Medicines, Inc.
Healthcare
|
Added | 185,000 | $61,936,150 | 2.84% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
Added | 590,000 | $56,150,300 | 2.57% | |
| ANAB |
Anaptysbio, Inc
Healthcare
|
Reduced | 826,109 | $55,762,357 | 2.55% | |
| AVTX |
Avalo Therapeutics, Inc.
Healthcare
|
Added | 2,900,000 | $53,592,000 | 2.45% | |
| CYTK |
Cytokinetics Inc
Healthcare
|
Reduced | 550,000 | $46,854,500 | 2.15% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Added | 250,000 | $46,820,000 | 2.14% | |
| ABVX |
Abivax S.A.
Healthcare
|
Reduced | 330,000 | $43,975,800 | 2.01% | |
| TRAX |
First Tracks Biotherapeutics, Inc.
Healthcare
|
NEW | 2,032,012 | $40,884,081 | 1.87% | |
| DNTH |
Dianthus Therapeutics, Inc.
Healthcare
|
Held | 400,000 | $38,992,000 | 1.79% | |
| STRO |
Sutro Biopharma, Inc.
Healthcare
|
Added | 1,172,487 | $38,926,568 | 1.78% | |
|
|
Reduced | 275,000 | $33,962,500 | 1.55% | ||
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
Reduced | 1,800,172 | $33,573,207 | 1.54% | |
|
CALL
|
NEW | 750,000 | $31,545,000 | 1.44% | ||
| OVID |
Ovid Therapeutics Inc.
Healthcare
|
Reduced | 10,144,562 | $27,288,871 | 1.25% | |
| LXEO |
Lexeo Therapeutics, Inc.
Healthcare
|
Added | 5,807,611 | $27,034,429 | 1.24% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Added | 700,000 | $26,047,000 | 1.19% | |
| BLTE |
Belite Bio, Inc
Healthcare
|
Added | 165,000 | $25,407,525 | 1.16% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Reduced | 500,000 | $25,375,000 | 1.16% | |
|
|
Added | 1,145,391 | $24,339,558 | 1.11% | ||
| LLY |
ELI LILLY & Co
CALL
Healthcare
|
NEW | 20,000 | $23,988,602 | 1.10% | |
| NRIX |
Nurix Therapeutics, Inc.
Healthcare
|
Held | 967,620 | $23,474,461 | 1.07% | |
| ANRO |
Alto Neuroscience, Inc.
Healthcare
|
Added | 850,000 | $22,431,500 | 1.03% | |
| MDGL |
Madrigal Pharmaceuticals, Inc.
Healthcare
|
Reduced | 40,000 | $21,478,000 | 0.98% | |
| PTGX |
Protagonist Therapeutics, Inc
Healthcare
|
Held | 172,125 | $21,099,082 | 0.97% | |
| MLYS |
Mineralys Therapeutics, Inc.
Healthcare
|
Held | 750,000 | $20,235,000 | 0.93% | |
| RLAY |
Relay Therapeutics, Inc.
Healthcare
|
Added | 1,050,000 | $19,645,500 | 0.90% | |
| SGMT |
Sagimet Biosciences Inc.
Healthcare
|
Added | 2,497,864 | $19,308,488 | 0.88% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Added | 840,350 | $18,672,577 | 0.85% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Reduced | 450,000 | $17,415,000 | 0.80% | |
| QURE |
uniQure N.V.
CALL
+ SHARES
Healthcare
|
Added | 375,000 | $17,272,500 | 0.79% | |
| TVTX |
Travere Therapeutics, Inc.
Healthcare
|
Held | 300,000 | $17,043,000 | 0.78% | |
| CGEM |
Cullinan Therapeutics, Inc.
Healthcare
|
Added | 875,760 | $15,947,589 | 0.73% | |
| SVRA |
Savara Inc
Healthcare
|
Held | 2,512,153 | $15,474,862 | 0.71% | |
| IDYA |
IDEAYA Biosciences, Inc.
Healthcare
|
NEW | 400,000 | $14,908,000 | 0.68% | |
| CATX |
Perspective Therapeutics, Inc.
Healthcare
|
Added | 4,214,582 | $14,371,724 | 0.66% | |
| ODTX |
Odyssey Therapeutics, Inc.
Healthcare
|
NEW | 766,346 | $14,338,333 | 0.66% | |
| OMER |
Omeros Corp
PUT
Healthcare
|
NEW | 1,411,300 | $13,421,463 | 0.61% | |
| HLXC |
Helix Acquisition Corp. III
Financial Services
|
Held | 1,250,000 | $13,300,000 | 0.61% | |
| EQ |
Equillium, Inc.
Healthcare
|
Added | 4,100,000 | $13,120,000 | 0.60% | |
| ESTA |
Establishment Labs Holdings Inc.
Healthcare
|
Added | 148,013 | $12,700,995 | 0.58% | |
| CLYM |
Climb Bio, Inc.
Healthcare
|
Added | 972,000 | $12,674,880 | 0.58% | |
| TEVA |
Teva Pharmaceutical Industries Ltd
Healthcare
|
Reduced | 374,000 | $12,671,120 | 0.58% |
Showing the top 50 of 107 positions. Create a free account to see every position, past quarters, search, filters and CSV export.
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.